Novel terminal deoxynucleotidyl transferase (TdT) variants and uses thereof - Patent Application 20070123333
Novel TdT variants with specific mutations improve enzyme stability and efficiency in incorporating modified nucleotides, reducing DNA synthesis errors and enhancing DNA quality.
Patent Information
- Application Number
- JP2024527290
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-10
- Publication Date
- 2024-11-08
AI Technical Summary
Existing enzyme-based DNA synthesis methods using template-free polymerases, such as terminal deoxynucleotidyl transferase (TdT), suffer from high error rates, particularly deletions, insertions, and substitutions, especially when synthesizing sequences with hairpin structures, due to inefficiencies in incorporating modified nucleotides.
Development of novel TdT variants with specific amino acid mutations, such as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, which enhance the incorporation of 3'-O-blocked nucleotides and reduce errors by stabilizing the enzyme, thereby improving DNA synthesis quality.
The novel TdT variants significantly decrease deletion rates from 0.55% to 0.32-0.40% per step, reducing overall synthesis errors by 0.04-0.06% per step, resulting in higher-quality DNA strands.
Smart Images

Figure 2024541312000004 
Figure 2024541312000005 
Figure 2024541312000006
Abstract
Description
[Technical field]
[0001] The present invention relates to novel DNA polymerases of the polX family, terminal deoxyribonuclease (TdT) variants containing at least one specific mutation or substitution, and uses thereof. [Background technology]
[0002] Synthetic biology is currently a research field that has been growing rapidly in recent years. It also offers the possibility of synthesizing biological materials. Thus, biological materials that do not exist in nature can be obtained, which leads to therapeutic or diagnostic solutions, such as genomic and diagnostic sequencing, multiplexed nucleic acid amplification, therapeutic antibody development, synthetic biology, nucleic acid-based therapeutics, DNA origami, DNA-based data storage, etc.
[0003] Gene synthesis is usually performed by chemical-based synthesis methods, but these methods have several problems: for one, for each nucleotide added, there is about a 0.5% chance of a genetic error, and the longer the sequence, the higher the chance of containing an error.
[0004] In recent years, there has been interest in supplementing or replacing chemical-based synthetic methods with enzyme-based methods using template-free polymerases such as terminal deoxynucleotidyl transferase (TdT), because of the proven efficiency of such enzymes, high synthesis rates, limited risk of errors, and the advantage of mild, non-toxic reaction conditions, e.g., Ybert et al., International Patent Publication No. WO 2015 / 159023; Hiatt et al., U.S. Pat. No. 5,763,594; Jensen et al., Biochemistry, 57:1821-1832 (2018), etc.
[0005] Most methods using enzyme-based synthesis require the use of reversibly blocked nucleoside triphosphates to obtain desired sequences in polynucleotide products.Unfortunately, template-free polymerases incorporate such modified nucleoside triphosphates with reduced efficiency compared to unmodified nucleoside triphosphates.Therefore, novel template-free polymerase variants with better incorporation efficiency directed toward modified nucleoside triphosphates have been developed, for example, Champion et al., US Patent Publication No. US2019 / 0211315 followed by International Patent Publication No. WO2021116270; Ybert et al., International Patent Publication No. WO2017 / 216472, etc.
[0006] With the development of novel template-free polymerase variants, the DNA quality during enzymatic DNA synthesis may be improved by reducing the risk of missing the incorporation of the desired nucleotide, such as substitution, deletion, or insertion during DNA synthesis. At least in part, these deletions are caused by the inability of template-free polymerases to incorporate the desired nucleotide, especially when the primer has a hairpin structure.
[0007] Therefore, there is a need for novel template-free polymerase variants to limit or prevent the number of substitutions or deletions during DNA synthesis and thus achieve synthesis of satisfactory DNA quality.
[0008] To address these needs, the inventors developed novel TdT variants and surprisingly discovered that more active TdT variants produce DNA or RNA strands with fewer misintegrations, such as deletions, insertions or substitutions, particularly during DNA synthesis. Summary of the Invention
[0009] Thus, the present invention relates to novel terminal deoxynucleotidyl transferase (TdT) variants with or without a linker moiety, which may by way of example have the sequence set forth in SEQ ID NO:6.
[0010] A novel terminal deoxynucleotidyl transferase (TdT) variant an amino acid sequence that is at least 70% identical to SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:2, optionally less than 100% identical to SEQ ID NO:2, said amino acid sequence comprising at least one amino acid substitution with a replacement amino acid at a position selected from a first group consisting of positions 23, 262, 264 and 298, or at a functionally equivalent position of each position in said first group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2; or an amino acid sequence at least 70% identical to SEQ ID NO:8, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:8, optionally less than 100% identical to SEQ ID NO:8, said amino acid sequence comprising at least one amino acid replacement with a replacement amino acid at a position selected from a second group consisting of positions 4, 243, 245 and 279, or at a functionally equivalent position of each position in said second group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:8; Includes.
[0011] In some embodiments, the novel TdT variant comprises the amino acid sequence set forth in SEQ ID NO:2, wherein the amino acid sequence comprises at least one amino acid substitution at an amino acid at a position selected from the group consisting of 23, 262, 264 and 298, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2.
[0012] In some embodiments, the novel TdT variant comprises an amino acid sequence as set forth in SEQ ID NO:8, the amino acid sequence comprising at least one amino acid substitution at an amino acid at a position selected from the group consisting of 4, 243, 245 and 279, wherein these positions are numbered by reference to the amino acid sequence as set forth in SEQ ID NO:8.
[0013] In another embodiment, the TdT variant comprises the amino acid sequence set forth in SEQ ID NO:1, said amino acid sequence comprising at least one amino acid substitution with another amino acid at a position selected from the group consisting of 23, 262, 264 and 298, or at a functionally equivalent position of each of said group of positions, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:1. In particular, said substituted amino acid is designated in SEQ ID NO:1 by "X".
[0014] In another embodiment, the TdT variant comprises the amino acid sequence set forth in SEQ ID NO:7, said amino acid sequence comprising at least one amino acid replacement with a replacement amino acid at a position selected from the group consisting of positions 4, 243, 245 and 279, or at a functionally equivalent position of each position, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:7. In particular, said replaced amino acid is designated in SEQ ID NO:7 by "X".
[0015] In certain embodiments, the terminal deoxynucleotidyl transferase (TdT) variant comprises two or more amino acid substitutions, preferably at least two amino acid substitutions, more preferably at least three amino acid substitutions in the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.
[0016] In certain embodiments, the terminal deoxynucleotidyl transferase (TdT) variant comprises two or more amino acid replacements, preferably at least two amino acid replacements, more preferably at least three amino acid replacements in the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8.
[0017] In some embodiments, the amino acid substituted in the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2 is selected from the group consisting of arginine (R), valine (V), alanine (A), leucine (L), lysine (K), glutamine (Q), threonine (T) and glycine (G).
[0018] In some embodiments, the amino acids replaced in the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8 are selected from the group consisting of arginine (R), valine (V), alanine (A), leucine (L), lysine (K), glutamine (Q), threonine (T) and glycine (G).
[0019] In certain embodiments, the TdT variant comprises an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
[0020] In certain embodiments, the TdT variant comprises an amino acid sequence selected from SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.
[0021] The present invention also relates to kits for performing template-free polynucleotide extension of any given sequence, where the kit comprises at least one TdT variant of the invention, at least one 3'-O-modified nucleoside triphosphate, and optionally at least one initiator. Such kits may further comprise deoxyribonucleoside triphosphates (dNTPs) for A, C, G and T for DNA extension, or ribonucleoside triphosphates (rNTPs) for rA, rC, rG and U for RNA extension.
[0022] Thus, the kit comprises at least one TdT variant according to the invention. In this regard, it is understood that the kit can comprise one TdT variant or multiple TdT variants, for example two different TdT variants.
[0023] In a particular embodiment, the kit comprises more than one TdT variant, in particular the kit comprises two TdT variants according to the invention, more preferably the kit comprises three TdT variants according to the invention.
[0024] In some embodiments, the kit comprises at least one TdT variant comprising an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5. In a particular embodiment, the kit comprises two TdT variants, a first TdT variant comprising an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and a second TdT variant comprising an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, but said second TdT variant is different from the first TdT variant. In another particular embodiment, the kit comprises three TdT variants according to the invention, more preferably the kit comprises a TdT variant comprising an amino acid sequence as set forth in SEQ ID NO:3, a TdT variant comprising an amino acid sequence as set forth in SEQ ID NO:4 and a TdT variant having an amino acid sequence as set forth in SEQ ID NO:5.
[0025] In some embodiments, the kit comprises at least one TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5. In certain embodiments, the kit comprises two TdT variants, a first TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and a second TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, but said second TdT variant is different from the first TdT variant.
[0026] In some embodiments, the kit comprises at least one TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11. In certain embodiments, the kit comprises two TdT variants, a first TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, and a second TdT variant comprising an amino acid sequence at least 70% identical to an amino acid sequence selected from SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, but said second TdT variant is different from the first TdT variant.
[0027] In some embodiments, the first TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:3, and the second variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:5.
[0028] In some embodiments, the first TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:9, and the second variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:11.
[0029] Advantageously, the TdT variants according to the invention overcome the technical problems of the prior art TdT variants, preventing deletions, insertions and reducing the incorporation of other undesirable triphosphates, e.g. chemically damaged dNTPs, during the enzymatic synthesis of nucleic acids.
[0030] The present invention also relates to a method of synthesizing a polynucleotide, the method comprising: a. providing at least one initiator having a 3'-terminal nucleotide having a free 3'-hydroxyl; b. contacting said at least one initiator having a free 3'-O-hydroxyl with a 3'-O-blocked nucleoside triphosphate and a TdT variant according to the invention under elongation conditions, such that said at least one initiator is elongated by incorporation of a 3'-O-blocked nucleoside triphosphate to form a 3'-O-blocked extension fragment; and c. deblocking the extension fragment to form an extension fragment having a free 3'-hydroxyl; and d. Repeating steps b. and c. until a polynucleotide is formed by contacting the extended fragment obtained in step c. under extension conditions; Includes.
[0031] In further embodiments, the invention includes at least one nucleic acid molecule encoding a TdT variant as described above, or in other words, the invention can include two or more nucleic acids, each of which encodes a protein sequence corresponding to a TdT variant as described.
[0032] The invention also includes at least one expression vector comprising such a nucleic acid molecule, and at least one host cell comprising said nucleic acid molecule or said expression vector. In yet a further embodiment, the invention includes a method for producing at least one TdT variant of the invention, wherein a host cell is cultured under culture conditions allowing expression of the nucleic acid encoding said TdT variant, and the TdT variant is optionally recovered. [Brief description of the drawings]
[0033] [Figure 1] FIG. 1 is a schematic illustrating the steps of a method of template-free enzymatic nucleic acid synthesis using a TdT variant of the invention. [Diagram 2] FIG. 1 shows hairpin (top) and duplex (bottom) iDNAs applied to measure the activity of TdT. [Diagram 3]FIG. 1 shows the activity and synthetic performance of TdT variants with SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, respectively with mutations T264R+I298V, or C23A+T264R+I298V, or V262A+I298V. Panel A: Enzyme kinetics of the +A reaction in the TAGCT+A duplex test. Panel B: Enzyme kinetics of the +G reaction with the CAGCAAGGCT+G hairpin. [Figure 4] FIG. 1 shows the average number of deletions, insertions and substitutions made during the synthesis of 24 sequences with TdT variants having sequence number 3, or sequence number 4 or sequence number 5, variants having the mutations T264R+I298V, or C23A+T264R+I298V, or V262A+I298V, respectively, compared to the synthesis performed with the TdT variant of sequence number 2 (referred to as reference). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] definition Amino acids are represented herein by one-letter or three-letter codes according to the following nomenclature: A: Ala (alanine), R: Arg (arginine), N: Asn (asparagine), D: Asp (aspartic acid), C: Cys (cysteine), Q: Gln (glutamine), E: Glu (glutamic acid), G: Gly (glycine), H: His (histidine), I: Ile (isoleucine), L: Leu (leucine), K: Lys (lysine), M: Met (methionine), F: Phe (phenylalanine), P: Pro (proline), S: Ser (serine), T: Thr (threonine), W: Trp (tryptophan), Y: Tyr (tyrosine), V: Val (valine) and X (undefined amino acid).
[0035] "Terminal deoxynucleotidyl transferase (TdT) variants" in the context of the present invention refers to a group of TdT mutants that share a series of mutations or alterations. The alterations or mutations can be substitutions, insertions, and / or deletions at one or more positions, allowing to preserve DNA polymerase activity. For example, one or two or three mutations at the same amino acid residue position, such as threonine being replaced by lysine at position 28. In particular, TdTs having the amino acid sequences set forth in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 are mutants, said TdTs sharing a series of mutations and constituting variants.
[0036] The TdT variant according to the present invention is a truncated TdT variant.TdT variant can be obtained by various techniques well known in the art.In particular, the examples of techniques for modifying the DNA sequence that codes for wild-type protein include, but are not limited to, site-directed mutagenesis, random mutagenesis, and construction of synthetic polynucleotides.
[0037] By "truncated TdT variant" in the context of the present invention is meant a TdT that does not contain the N-terminal portion of the corresponding wild-type TdT. A TdT variant according to the present invention is an N-terminal truncated TdT that lacks amino acid residues 1 to 132 of the corresponding wild-type parent NP_001036693.1 (Mus musculus) TdT sequence.
[0038] By "undetermined amino acid" or "unknown amino acid" or "X" in the context of the present invention is meant an amino acid that can be one of the 20 amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
[0039] A "substituted amino acid" or "replaced amino acid" in the context of the present invention refers to the replacement of an original amino acid (before substitution or mutation) with another amino acid at a specific position, in particular at a position selected from a first group consisting of positions 23, 262, 264 and 298, as numbered by reference to the amino acid sequence set forth in SEQ ID NO: 2, or at a position selected from a second group consisting of positions 4, 243, 245 and 279, as numbered by reference to the amino acid sequence set forth in SEQ ID NO: 8. For example, at position 23 of SEQ ID NO: 2 or at position 4 of SEQ ID NO: 8, the original amino acid is C and the substituted amino acid is A.
[0040] "% of identity" or "percentage of identity" or "at least % identical to" in the sense of the present invention between two nucleic acid sequences or two amino acid sequences is understood to refer to the percentage of nucleotides or amino acid residues that are identical between the two sequences being compared, this percentage being obtained after best alignment, this percentage being purely statistical, the differences between the two sequences being distributed randomly and over their entire length. The best alignment of sequences for comparison can be done manually, or by using the local homology algorithm of Smith and Waterman (1981) (Ad. App. Math. 2:482), by using the local homology algorithm of Neddleman and Wunsch (1970) (J. Mol. Biol. 48:443), by using the similarity search method of Pearson and Lipman (1988) (Proc. Natl. Acad. Sci. USA 85:2444), by using computer software that uses these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by using the online alignment software Mutalin (http: / / multalin.toulouse.inra.fr / multalin / multalin.html; 1988, Nucl. Acids. Res., 16(22), pp. 10881-10890).
[0041] In the sense of the present invention, "functionally equivalent sequences" are understood to mean sequences of DNA polymerases of the poIX family, in particular sequences having at least 70%, 75%, 80%, 85%, 90%, preferably at least 95%, 97%, 99%, identity to SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:7 or SEQ ID NO:8, i.e. sequences of TdT having an amino acid sequence and having the same functional role.
[0042] "Functionally equivalent residue" is understood to mean a residue in a sequence of a DNA polymerase of the poIX family that has a sequence homologous to SEQ ID NO: 2 or SEQ ID NO: 8 and has the same functional role. Thus, a "functionally equivalent position" is the position of the functionally equivalent residue in the homologous sequence.
[0043] Functionally equivalent residues are identified using sequence alignment, for example, performed with the online alignment software Mutalin (http: / / multalin.toulouse.inra.fr / multalin / multalin.html; 1988, Nucl.Acids Res., 16(22), pp. 10881-10890). After alignment, functionally equivalent residues are located at homologous positions on the different sequences considered. Sequence alignment and identification of functionally equivalent residues can be performed between DNA polymerases of the poIX family and their naturally occurring variants, including interspecies variants.
[0044] "Containing at least one amino acid substitution" or "contains at least one amino acid mutation" in the sense of the present invention is understood to mean that the variant has one or more substitutions or mutations as indicated in relation to the sequence of SEQ ID NO:1 or SEQ ID NO:2, but the variant can have other modifications, in particular substitutions, deletions or additions.
[0045] "Containing at least one amino acid replacement" in the sense of the present invention is understood to mean that the variant has one or more substitutions or mutations as indicated in relation to the sequence of SEQ ID NO: 7 or SEQ ID NO: 8, but the variant can have other modifications, in particular substitutions, deletions or additions.
[0046] The present invention relates to a variant of poIX family DNA polymerase, in particular, a stabilized variant of TdT polymerase that can be used to synthesize polynucleotides such as DNA or RNA without template strand.The TdT variant of the present invention allows modified nucleotides, more specifically 3'O-reversibly modified nucleoside triphosphates, to be used in enzyme-based methods of polynucleotide synthesis.In particular, the TdT variant is a truncated TdT variant, more specifically, an N-terminal truncated TdT variant.
[0047] Template-free enzymatic synthesis Template-free enzymatic synthesis of polynucleotides can be performed by a variety of known protocols using a template-free polymerase such as terminal deoxynucleotidyl transferase (TdT), including variants thereof engineered to have improved properties such as greater temperature stability or greater efficiency in the incorporation of 3'-O-blocked deoxynucleoside triphosphates (3'-O-blocked dNTPs), see, for example, Ybert et al., International Patent Publication No. WO / 2015 / 159023; Ybert et al., International Patent Publication No. WO / 2017 / 216472; Hyman, U.S. Pat. No. 5,436,143; Hiatt et al., U.S. Pat. No. 5,763,594; Jensen et al., Biochemistry, 57:1821-1832 (2018); Mathews et al., Organic & Biomolecular Chemistry, DOI: 0.1039 / c6ob01371f (2016); Schmitz et al., Organic Lett., 1(11):1729-1731 (1999).
[0048] In some embodiments, the method of enzymatic DNA synthesis involves repeated cycles of steps, such that a nucleotide is added in each cycle, as illustrated in Figure 1. An initiator polynucleotide (100) is provided, for example attached to a solid support (102), which has a free 3'-hydroxyl group (103). To the initiator polynucleotide (100) (or an initiator polynucleotide extended in a subsequent cycle), a 3'-O-protected dNTP and a TdT variant (104) are added under conditions effective for enzymatic incorporation of the 3'-O-protected dNTP onto the 3' end of the initiator polynucleotide (100) (or extended initiator polynucleotide). This reaction produces an extended initiator polynucleotide (106) whose 3'-hydroxyl is protected.
[0049] In other words, a method for synthesizing a polynucleotide comprises the steps of: a. providing at least one initiator having a 3'-terminal nucleotide having a free 3'-hydroxyl; b. contacting said at least one initiator having a free 3'-O-hydroxyl with a 3'-O-blocked nucleoside triphosphate and a TdT variant according to the invention under elongation conditions, such that the initiator is elongated by incorporation of a 3'-O-blocked nucleoside triphosphate to form a 3'-O-blocked extension fragment; c. deblocking the extension fragment to form an extension fragment having a free 3'-hydroxyl; and d. Repeating steps b. and c. by contacting the extended fragment obtained in step c. under extension conditions until a polynucleotide is formed.
[0050] When the extended initiator polynucleotide contains the completed sequence, the 3'-O-protecting group is removed or deprotected, and the desired sequence is cleaved from the original initiator polynucleotide. Such cleavage can be performed by using any of a variety of single-strand cleavage techniques, for example, by inserting a cleavable nucleotide or a cleavable linker at a predetermined position in the original initiator polynucleotide. Exemplary cleavable nucleotides or linkers include, but are not limited to, (i) uracil nucleotides that are cleaved by uracil DNA glycosylase; (ii) photocleavable groups such as nitrobenzyl linkers, as described in U.S. Pat. No. 5,739,386; or inosine that is cleaved by endonuclease V.
[0051] In some embodiments, the cleaved polynucleotide can have a free 5'-hydroxyl; in other embodiments, the cleaved polynucleotide can have a 5' phosphorylated terminus. If the extended initiator polynucleotide does not contain the completed sequence, the 3'-O-protecting group is removed to expose the free 3'-hydroxyl (103) and the extended initiator polynucleotide is subjected to another cycle of nucleotide addition and deprotection.
[0052] As used herein, the terms "protected" and "blocked" in reference to a particular group, such as the 3'-hydroxyl of a nucleotide or nucleoside, are used interchangeably to mean a moiety that is covalently attached to the particular group and prevents chemical modification to that group during a chemical or enzymatic process. Whenever the particular group is the 3'-hydroxyl of a nucleoside triphosphate or an extension fragment (or "extension intermediate") incorporating a 3'-protected (or blocked)-nucleoside triphosphate, the chemical modification that is prevented is the further or subsequent extension of the extension fragment (or "extension intermediate") by an enzymatic coupling reaction.
[0053] In some embodiments, the aligned sequence of nucleotides is coupled to the initiator nucleic acid using TdT in the presence of 3'-O-reversibly blocked dNTPs in each synthesis step. In some embodiments, the method of synthesizing a polynucleotide includes the steps of: (a) providing an initiator having a free 3'-hydroxyl; (b) reacting the initiator having a free 3'-hydroxyl or an extension intermediate with TdT under extension conditions in the presence of a 3'-O-blocked nucleoside triphosphate to generate a 3'-O-blocked extension intermediate; (c) deblocking the extension intermediate to generate an extension intermediate with a free 3'-hydroxyl; and (d) repeating steps (b) and (c) until a polynucleotide is synthesized. Sometimes, the "extension intermediate" is also referred to as an "extension fragment".
[0054] In some embodiments, the initiator is provided as an oligonucleotide, for example attached by its 5' end to a solid support. The above method may also include a washing step after the reaction or extension step, as well as after the deblocking step. For example, the reacting step may include a substep of removing unincorporated nucleoside triphosphates, for example by washing, after a given incubation period or reaction time. Such a given incubation period or reaction time may be from a few seconds, for example 30 seconds, to a few minutes, for example 30 minutes.
[0055] The above method can also include a capping step and a washing step after the reaction or extension step and after the deblocking step. As mentioned above, in some embodiments, a capping step can be included, in which the non-extended free 3'-hydroxyl is reacted with a compound that prevents any further extension of the capped strand. In some embodiments, such a compound can be a dideoxynucleoside triphosphate. In other embodiments, non-extended strands with free 3'-hydroxyl can be degraded by treating them with 3'-exonuclease activity, e.g., Exo I. See, for example, US Patent No. 5,436,143 to Hyman. Similarly, in some embodiments, strands that cannot be deblocked can be treated to remove the strand or to render the strand inactive for further extension.
[0056] In some embodiments involving sequential synthesis of polynucleotides, the capping step may not be desirable because capping may prevent the generation of multiple polynucleotides in equimolar amounts.Without capping, the sequence will have a uniform distribution of deletion errors, but each of the multiple polynucleotides will be present in equimolar amounts.This may not be the case when non-extended fragments are capped.
[0057] In some embodiments, reaction conditions for the extension or elongation step can include: 2.0 μM purified TdT; 125-600 μM 3'-O-blocked dNTP (e.g., 3'-O-NH2-blocked dNTP); about 10 to about 500 mM potassium cacodylate buffer (pH between 6.5 and 7.5), and about 0.01 to about 10 mM divalent cation (e.g., CoC12 or MnC12), in which case the extension reaction can be carried out for 3 minutes in a reaction volume of 50 μL at a temperature ranging from room temperature to 45° C. In embodiments where the 3'-O-blocked dNTP is a 3'-O-NH2-blocked dNTP, the reaction conditions for the deblocking step may include: 700 mM NaNO2; 1 M sodium acetate (adjusted to a pH in the range of 4.8-6.5 with acetic acid), in which case the deblocking reaction may be carried out in a volume of 50 μL at a temperature in the range of room temperature to 45° C. for 30 seconds to several minutes.
[0058] Depending on the particular application, the deblocking and / or cleaving steps can include various chemical or physical conditions, such as light, heat, pH, the presence of specific reagents, such as enzymes, that can cleave specific chemical bonds. Guidance on selecting 3'-O-blocking groups and corresponding deblocking conditions can be found in the following references, which are incorporated by reference: U.S. Pat. No. 5,808,045; U.S. Pat. No. 8,808,988; International Patent Publication No. WO91 / 06678; and the references cited below. In some embodiments, the cleaving agent (also sometimes referred to herein as deblocking reagent or deblocking agent) is a chemical cleaving agent, such as, for example, dithiothreitol (DTT). In alternative embodiments, the cleaving agent can be an enzymatic cleaving agent, such as, for example, a phosphatase, that can cleave 3'-phosphate blocking groups. Those skilled in the art will appreciate that the choice of deblocking agent will depend on the type of 3'-nucleotide blocking group used, whether one or more blocking groups are used, whether the initiator is attached to a living cell or organism that requires gentle treatment, or to a solid support, etc. For example, a phosphine such as tris(2-carboxyethyl)phosphine (TCEP) can be used to cleave a 3'O-azidomethyl group, a palladium complex can be used to cleave a 3'O-allyl group, or sodium nitrite can be used to cleave a 3'O-amino group. In certain embodiments, the cleavage reaction involves TCEP, a palladium complex, or sodium nitrite.
[0059] As mentioned above, in some embodiments, it is desirable to use two or more blocking groups that can be removed using orthogonal deblocking conditions. The following exemplary pairs of blocking groups can be used in parallel synthesis embodiments such as those described above. It is understood that other pairs of blocking groups or groups containing more than two may be available for use in these embodiments of the invention. TIFF2024541312000001.tif64170
[0060] Synthesis of oligonucleotides in living cells requires mild deblocking or deprotection conditions, i.e., conditions that do not disrupt cell membranes, denature proteins, interfere with key cell functions, etc. In some embodiments, the deprotection conditions are within physiological conditions that are compatible with cell viability. In such embodiments, enzymatic deprotection is desirable because it can be performed under physiological conditions. In some embodiments, enzymatically removable specific blocking groups are associated with enzymes specific for their removal. For example, ester- or acyl-based blocking groups can be removed using esterases such as acetyl esterases or similar enzymes, and phosphate blocking groups can be removed using 3' phosphatases such as T4 polynucleotide kinase. By way of example, 3'-O-phosphates can be removed by treatment with a solution such as 100 mM Tris-HCl (pH 6.5), 10 mM MgCl2, 5 mM 2-mercaptoethanol, and 1 unit of T4 polynucleotide kinase. The reaction proceeds for 1 minute at a temperature of 37°C.
[0061] "3'-phosphate blocked" or "3'-phosphate protected" nucleotide refers to a nucleotide in which the hydroxyl group at the 3' position is blocked by the presence of a phosphate-containing moiety. Examples of 3'-phosphate blocked nucleotides according to the present invention are nucleotidyl-3'-phosphate monoester / nucleotidyl-2',3'-cyclic phosphate, nucleotidyl-2'-phosphate monoester and nucleotidyl-2' or 3'-alkyl phosphate diester, and nucleotidyl-2' or 3'-pyrophosphate. Thiophosphate or other analogs of such compounds can also be used, provided that such substitution does not prevent dephosphorylation and provides a free 3'-OH by phosphatase.
[0062] Further examples of the synthesis and enzymatic deprotection of 3'-O-ester protected dNTPs or 3'-O-phosphate protected dNTPs are described in the following references: Canard et al., Proc. Natl. Acad. Sci., 92:10859-10863 (1995); Canard et al., Gene, 148:1-6 (1994); Cameron et al., Biochemistry, 16(23):5120-5126 (1977); Rasolonjatovo et al., Nucleosides & Nucleotides, 18(4&5):1021-1022 (1999); Ferrero et al., Monatshefte fur Chemie, 131:585-616 (2000); Taunton-Rigby et al., J. Org. Chem., 38(5):977-985 (1973); Uemura et al., Tetrahedron Lett., 30(29):3819-3820 (1989); Becker et al., J. Biol. Chem., 242(5):936-950 (1967); Tsien, International Patent Publication No. WO 1991 / 006678.
[0063] As used herein, "initiator" (or equivalent terms such as "initiating fragment", "initiator nucleic acid", "initiator oligonucleotide", etc.) refers to a short oligonucleotide sequence with a free 3' end that can be further extended by a template-free polymerase such as TdT. In one embodiment, the initiating fragment is a DNA initiating fragment. In an alternative embodiment, the initiating fragment is an RNA initiating fragment. In some embodiments, the initiating fragment possesses between 3 and 100 nucleotides, particularly between 3 and 20 nucleotides. In some embodiments, the initiating fragment is single-stranded. In alternative embodiments, the initiating fragment is double-stranded. In certain embodiments, initiator oligonucleotides synthesized with a 5'-primary amine can be covalently linked to magnetic beads using the manufacturer's protocol. Similarly, initiator oligonucleotides synthesized with a 3'-primary amine can be covalently linked to magnetic beads using the manufacturer's protocol. A variety of other attachment chemistries suitable for use with embodiments of the present invention are known in the art, e.g., Integrated DNA Technologies brochure, "Strategies for Attaching Oligonucleotides to Solid Supports", Vol. 6 (2014); Hermanson, Bioconjugate Techniques, 2nd Edition (Academic Press, 2008); and similar publications.
[0064] Many of the 3'-O-blocked dNTPs used in the present invention may be purchased from commercial vendors or may be synthesized using published techniques, e.g., U.S. Patent No. 7,057,026; International Patent Publication Nos. WO 2004 / 005667, WO 91 / 06678; Canard et al., Gene (cited above); Metzker et al., Nucleic Acids Research, 22:4259-4267 (1994); Meng et al., J. Org. Chem., 14:3248-3252 (3006); U.S. Patent Publication No. 2005 / 037991. In some embodiments, the modified nucleotides include modified nucleotide or nucleoside molecules that include a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a covalently attached, removable 3'-OH blocking group such that the 3' carbon atom has the structure: -OZ The group is attached wherein -Z is any of -C(R')2-O-R'', -C(R')2-N(R'')2, -C(R')2-N(H)R'', -C(R')2-S-R'', and -C(R')2-F, where each R'' is or is part of a removable protecting group; each R' is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy, or amido group, or a detectable label attached through a linking group; with the proviso that in some embodiments such substituents are selected from the group consisting of up to 10 carbon atoms and / or up to 5 oxygen or nitrogen heteroatoms. or (R')2 represents a group of formula =C(R''')2, where each R''' may be the same or different and is selected from the group consisting of hydrogen and halogen atoms and alkyl groups, with the proviso that in some embodiments, the alkyl of each R''' has from 1 to 3 carbon atoms; and where the molecule reacts to provide an intermediate in which each R'' is replaced with H, or, when Z is -(R')2-F, an intermediate in which F is replaced with OH, SH or NH2, preferably OH, which dissociates under aqueous conditions to provide a molecule with a free 3'-OH; with the proviso that when Z is -C(R')2-S-R'', both R' groups are not H. In certain embodiments, R' of the modified nucleotide or nucleoside is alkyl or substituted alkyl, with the proviso that such alkyl or substituted alkyl has from 1 to 10 carbon atoms and from 0 to 4 oxygen or nitrogen heteroatoms. In certain embodiments, -Z of the modified nucleotide or nucleoside is of the formula -C(R')-N. In certain embodiments, Z is an azidomethyl group.
[0065] In some embodiments, Z is a cleavable organic moiety with or without heteroatoms having a molecular weight of 200 or less. In other embodiments, Z is a cleavable organic moiety with or without heteroatoms having a molecular weight of 100 or less. In other embodiments, Z is a cleavable organic moiety with or without heteroatoms having a molecular weight of 50 or less. In some embodiments, Z is an enzymatically cleavable organic moiety with or without heteroatoms having a molecular weight of 200 or less. In other embodiments, Z is an enzymatically cleavable organic moiety with or without heteroatoms having a molecular weight of 100 or less. In other embodiments, Z is an enzymatically cleavable organic moiety with or without heteroatoms having a molecular weight of 50 or less. In other embodiments, Z is an enzymatically cleavable ester group with a molecular weight of 200 or less. In other embodiments, Z is a phosphate group removable by a 3'-phosphatase. In some embodiments, one or more of the following 3'-phosphatases can be used using the manufacturer's recommended protocols: T4 polynucleotide kinase, calf intestinal alkaline phosphatase, recombinant shrimp alkaline phosphatase (available, for example, from New England Biolabs, Beverly, Mass.).
[0066] In further specific embodiments, the 3'-blocked nucleotide triphosphate is blocked by either a 3'-O-azidomethyl, 3'-O-NH2 or 3'-O-allyl group. In other embodiments, the 3'-blocked nucleotide triphosphate is blocked by either a 3'-O-azidomethyl, 3'-O-NH2 or 3'-O-allyl group.
[0067] In some embodiments, 3'-O-blocking groups of the present invention include 3'-O-methyl, 3'-O-(2-nitrobenzyl), 3'-O-allyl, 3'-O-amine, 3'-O-azidomethyl, 3'-O-tert-butoxyethoxy, 3'-O-(2-cyanoethyl), and 3'-O-propargyl.
[0068] TdT variants According to a first aspect of the invention, a TdT variant according to the invention comprises the amino acid sequence set forth in SEQ ID NO: 2, said amino acid sequence comprising at least one amino acid substitution with an amino acid at a position selected from the group consisting of positions 23, 262, 264 and 298, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO: 2. In particular, a TdT variant according to the invention is (i) capable of synthesizing nucleic acid fragments without a template and (ii) capable of incorporating 3'-O-modified nucleotides into nucleic acid fragments.
[0069] In a particular embodiment, said amino acid sequence may comprise two or more amino acid substitutions, preferably at least two or three, selected from the group consisting of positions 23, 262, 264 and 298. Said TdT variant is capable of synthesizing a DNA strand and / or an RNA strand.
[0070] In another embodiment, a TdT variant according to the invention has an amino acid sequence as set forth in SEQ ID NO:1, said amino acid sequence comprising at least one amino acid substitution at an amino acid at a position selected from the group consisting of 23, 262, 264 and 298, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO: 1. The TdT variant having the amino acid sequence set forth in SEQ ID NO: 1 comprises at least one undetermined amino acid at a position selected from the group consisting of positions 23, 262, 264 and 298. The undetermined amino acids in the sequence are designated in SEQ ID NO: 1 by an "X."
[0071] According to a second aspect of the invention, the TdT variant according to the invention comprises an amino acid sequence at least 70% identical to SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:2, optionally less than 100% identical to SEQ ID NO:2, said amino acid sequence comprising at least one amino acid substitution with a replacement amino acid at a position selected from a first group consisting of positions 23, 262, 264 and 298 or at a functionally equivalent position of each position in said first group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2. In particular, the TdT variant according to the invention is (i) capable of synthesizing nucleic acid fragments without a template and (ii) capable of incorporating 3'-O-modified nucleotides into nucleic acid fragments.
[0072] In a particular embodiment, said amino acid sequence may comprise two or more amino acid substitutions, preferably at least two or three, selected from the group consisting of positions 23, 262, 264 and 298. Said TdT variant is capable of synthesizing a DNA strand and / or an RNA strand.
[0073] In another embodiment, the TdT variant according to the invention has an amino acid sequence at least 70% identical to SEQ ID NO: 1, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 1, optionally less than 100% identical to SEQ ID NO: 1, said amino acid sequence comprising at least one amino acid substitution with a replacement amino acid at a position selected from the group consisting of positions 23, 262, 264 and 298 or at a functionally equivalent position of each position in said first group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO: 1. Said TdT variant having an amino acid sequence at least 70% identical to SEQ ID NO: 1 comprises at least one undetermined amino acid at a position selected from the first group consisting of positions 23, 262, 264 and 298 or at a functionally equivalent position of each position in said first group. Undetermined amino acids in the sequence are designated in SEQ ID NO: 1 by "X".
[0074] According to a second aspect of the invention, the TdT variant according to the invention comprises: The TdT variants according to the invention comprise an amino acid sequence at least 70% identical to SEQ ID NO:8, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:8, optionally less than 100% identical to SEQ ID NO:8, said amino acid sequence comprising at least one amino acid replacement with a replacement amino acid at a position selected from the second group consisting of positions 4, 243, 245 and 279 or at a functionally equivalent position of each position in said second group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:8. In particular, the TdT variants according to the invention are (i) capable of synthesizing nucleic acid fragments without a template and (ii) capable of incorporating 3'-O-modified nucleotides into nucleic acid fragments.
[0075] In a particular embodiment, said amino acid sequence can comprise two or more amino acid replacements, preferably at least two or three, selected from the second group consisting of positions 4, 243, 245 and 279. Said TdT variant is capable of synthesizing a DNA strand and / or an RNA strand.
[0076] In another embodiment, the TdT variant according to the invention has an amino acid sequence at least 70% identical to SEQ ID NO:7, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:7, optionally less than 100% identical to SEQ ID NO:7, said amino acid sequence comprising at least one amino acid replacement with a replacement amino acid at a position selected from the group consisting of positions 4, 243, 245 and 279 or at a functionally equivalent position of each position in said first group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:7. Said TdT variant having an amino acid sequence at least 70% identical to SEQ ID NO:7 comprises at least one undetermined amino acid at a position selected from the second group consisting of positions 4, 243, 245 and 279 or at a functionally equivalent position of each position in said second group. Undetermined amino acids in the sequence are designated in SEQ ID NO:7 by "X".
[0077] In another embodiment, the TdT variant comprises the amino acid sequence set forth in SEQ ID NO:2, which comprises at least one amino acid substitution with an amino acid at a position corresponding to a residue selected from the group consisting of C23, V262, T264 and I298, where these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2. For example, residue C23 corresponds to the cysteine amino acid at position 23 prior to substitution.
[0078] In another embodiment, a TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:2, said amino acid sequence comprising at least one amino acid substitution with a replacement amino acid at a position corresponding to a residue selected from the group consisting of C23, V262, T264 and I298, or at a functionally equivalent position of each position in said group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2. For example, residue C23 corresponds to the cysteine amino acid at position 23 prior to substitution.
[0079] In another embodiment, the TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:2, said amino acid sequence comprising at least one amino acid replacement with a replacement amino acid at a position corresponding to a residue selected from the group consisting of C4, V243, T245 and I279 or at a functionally equivalent position of each position in said group, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:8. For example, residue C4 corresponds to the cysteine amino acid at position 23 prior to the replacement. According to any one of the previous embodiments, said replacements correspond to TdT residues located within the flexible loop L1 - the region of the protein involved in the binding of dNTPs to iDNA - but also to TdT residues located within the core of the catalytic domain - the region of the protein involved in the chemical step of the reaction (nucleotidyl exotransferase activity) - and to TdT residues located in the C-terminal domain - the region of the protein involved in iDNA binding and the overall folding of TdT. Said substitutions at certain positions, especially in the flexible loop L1, improve the reaction yield towards the alpha phosphate of dNTPs due to better alignment between the TdT 3'OH of the iDNA.
[0080] In some embodiments, a TdT variant according to the invention comprises the amino acid sequence set forth in SEQ ID NO:2 or a functionally equivalent sequence set forth in SEQ ID NO:2, which comprises at least one amino acid substitution with an amino acid at a position selected from the group consisting of 23, 262, 264 and 298, wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2.
[0081] In the context of the present invention, the TdT variant may be from any species or may be a chimeric protein. By "chimeric protein" is meant that the parts of the variant are from at least two different species. The chimeric protein is formed by the addition, particularly by fusion or conjugation, of one or more predetermined sequences of a protein of one species with at least one other predetermined sequence of a second species, which is a member of the poIX family, particularly TdT. Preferably, the TdT variant is a chimeric protein, more preferably, the chimeric protein comprises parts from two different species, particularly a predetermined sequence from mouse and a predetermined sequence from bovine.
[0082] In certain embodiments, a TdT variant according to the invention comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90% identity or homology with the amino acid sequence according to SEQ ID NO:1 or set forth in SEQ ID NO:2, preferably at least 95%, 96%, 97%, 98%, 99% and less than 100% identity with the sequence according to SEQ ID NO:1 or in SEQ ID NO:2.
[0083] In another specific embodiment, the TdT variant according to the invention comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90% identity or homology to an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, more preferably at least 95%, 96%, 97%, 98%, 99% and less than 100% identity to a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
[0084] In certain embodiments, at least one amino acid substitution at a replacement amino acid at a position selected from the group consisting of 23, 262, 264 and 298 is selected from the group consisting of R, V, A, L, K, Q, T and G. More preferably, the substituted amino acid is at position 298, the indicated positions being determined by alignment with SEQ ID NO:1 or SEQ ID NO:2.
[0085] In certain embodiments, at least one amino acid replacement with a replacement amino acid at a position selected from the group consisting of 4, 243, 245 and 279 is selected from the group consisting of R, V, A, L, K, Q, T and G. More preferably, the replaced amino acid is at position 279, the indicated position being determined by alignment with SEQ ID NO:7 or SEQ ID NO:8.
[0086] In some embodiments, the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2 comprises at least two substitutions at positions selected from the group consisting of 23, 262, 264 and 298. Preferably, the first substitution is at position 298 and the second substitution is at a position selected from the group consisting of 23, 262 and 264.
[0087] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:1 or SEQ ID NO:2 contains at least two substitutions at positions selected from the group consisting of 23, 262, 264 and 298. Preferably, the first substitution is at position 298 and the second substitution is at a position selected from the group consisting of 23, 262 and 264.
[0088] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:7 or SEQ ID NO:8 contains at least two substitutions at positions selected from the group consisting of: 4, 243, 245, and 279. Preferably, the first substitution is at position 279 and the second substitution is at a position selected from the group consisting of: 4, 243, and 245.
[0089] In certain embodiments, at least two of the substitutions are selected from the group consisting of R, V, A, L, K, Q, T and G.
[0090] In certain embodiments, the at least two substitutions are selected from the group consisting of R, V, A, L, K, Q, T and G. In some embodiments, the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2 comprises at least three substitutions at positions selected from the group consisting of 23, 262, 264 and 298. Preferably, the first substitution is at position 298, the second substitution is at position 23 or 264, and the third substitution is also at position 23 or 264.
[0091] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:1 or SEQ ID NO:2 comprises at least three substitutions at positions selected from the group consisting of 23, 262, 264 and 298. Preferably, the first substitution is at position 298, the second substitution is at position 23 or 264, and the third substitution is also at position 23 or 264.
[0092] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:7 or SEQ ID NO:8 comprises at least three substitutions at positions selected from the group consisting of 4, 243, 245, and 279. Preferably, the first substitution is at position 279, the second substitution is at position 4 or 245, and the third substitution is also at position 4 or 245.
[0093] In certain embodiments, the three substitutions are selected from the group consisting of R, V, A, L, K, Q, T and G.
[0094] In certain embodiments, the three replacements are selected from the group consisting of R, V, A, L, K, Q, T and G.
[0095] In a particular embodiment, the amino acid sequence of the TdT variant according to the invention as set forth in SEQ ID NO: 2 comprises at least one amino acid substitution selected from I298V / T / L. By "I298V / T / L" this means that isoleucine is substituted at position 298 by an amino acid selected from valine (V), threonine (T) and leucine (L). Preferably, the at least one amino acid substitution is I298 / V.
[0096] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least one amino acid substitution selected from I298V / T / L.
[0097] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid replacement selected from I279V / T / L.
[0098] In another particular embodiment, the amino acid sequence of the TdT variant according to SEQ ID NO: 2 comprises at least one amino acid substitution selected from T264R / K / Q. By "T264R / K / Q" it is meant that threonine is substituted at position 264 by an amino acid selected from arginine (R), leucine (K) and glutamine (Q). Preferably, the at least one amino acid substitution is T264 / R.
[0099] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least one amino acid substitution selected from T264R / K / Q.
[0100] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid substitution selected from T245R / K / Q.
[0101] In another particular embodiment, the amino acid sequence of the TdT variant set forth in SEQ ID NO:2 comprises at least one amino acid substitution selected from V262A / T / G. By "V262A / T / G" it is meant that valine is substituted at position 262 by an amino acid selected from alanine (A), threonine (T) and glycine (G). Preferably, the at least one amino acid substitution is V262A.
[0102] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least one amino acid substitution selected from V262A / T / G.
[0103] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid replacement selected from V243A / T / G.
[0104] In another particular embodiment, the amino acid sequence of the TdT variant according to SEQ ID NO: 2 comprises at least one amino acid substitution selected from C23A / T. By "C23A / T" it is meant that a cysteine is substituted at position 23 by the amino acids alanine (A) or threonine (T). Preferably, the at least one amino acid substitution is C23A.
[0105] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least one amino acid substitution selected from C23A / T.
[0106] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid substitution selected from C4A / T.
[0107] In some embodiments, the amino acid sequence of the TdT variant set forth in SEQ ID NO:2 comprises at least two amino acid substitutions selected from C23A / T, V262A / T / G, T264R / K / Q and I298V / T / L, preferably the two amino acid substitutions are T264R / K / Q and I298V / T / L, or C23A / T and I298V / T / L, or V262A / T / G and I298V / T / L.
[0108] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least two amino acid substitutions selected from C23A / T, V262A / T / G, T264R / K / Q and I298V / T / L, preferably the two amino acid substitutions are T264R / K / Q and I298V / T / L, or C23A / T and I298V / T / L, or V262A / T / G and I298V / T / L.
[0109] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least two amino acid substitutions selected from C4A / T, V243A / T / G, T245R / K / Q and I279V / T / L, preferably the two amino acid substitutions are T245R / K / Q and I279V / T / L, or C4A / T and I279V / T / L, or V243A / T / G and I279V / T / L.
[0110] In another preferred embodiment, the amino acid sequence of the TdT variant set forth in SEQ ID NO:2 contains three amino acid substitutions: C23A / T, and T264R / K / Q, and I298V / T / L.
[0111] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains three amino acid substitutions: C23A / T, and T264R / K / Q, and I298V / T / L.
[0112] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains three amino acid substitutions that are C4A / T, and T245R / K / Q, and I279V / T / L.
[0113] In some embodiments, the at least one amino acid substitution is at position 298.
[0114] In some embodiments, the at least one amino acid substitution is at position 279.
[0115] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least two substitutions at positions selected from the group consisting of 23, 262, 264, and 298.
[0116] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least two substitutions at positions selected from the group consisting of 4, 243, 245, and 279.
[0117] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:2 contains at least three substitutions at positions selected from the group consisting of 23, 262, 264 and 298.
[0118] In some embodiments, the amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least three substitutions at positions selected from the group consisting of 4, 243, 245, and 279.
[0119] In a preferred embodiment, the TdT variants of the present invention are chimeric variants, as listed in Table 1 below. TIFF2024541312000002.tif123170
[0120] In some embodiments, the TdT variant comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5; preferably, the TdT variant has the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:5; more preferably, the TdT variant has the amino acid sequence set forth in SEQ ID NO:5.
[0121] In some embodiments, the TdT variant comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, preferably the TdT variant has the amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:11, more preferably the TdT variant has the amino acid sequence set forth in SEQ ID NO:11.
[0122] In some embodiments, a TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:2 is at least 70% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, and optionally less than 100% identical thereto.
[0123] A TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:8 is at least 70% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, and optionally less than 100% identical thereto.
[0124] The specific TdT variants according to the present invention improve the quality of DNA synthesis and then solve technical problems.In particular, the TdT variants with amino acid sequences as set forth in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 have a reduction in the deletion rate for alanine, respectively, from 0.55% per step to 0.36%, 0.32% and 0.40%, compared with the deletion rate of the TdT variant with amino acid sequence as set forth in SEQ ID NO:2.The same TdT variants reduce the overall synthesis error rate by 0.04%, 0.06% and 0.06% per step, respectively.Therefore, the specific TdT variants according to the present invention are more stable than the TdT variant with amino acid sequence as set forth in SEQ ID NO:2.
[0125] Also in particular, TdT variants having an amino acid sequence at least 70% identical to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11 have a reduced deletion rate for alanine of 0.55% to 0.36%, 0.32% and 0.40% per step compared to the deletion rate of TdT variants having the amino acid sequence set forth in SEQ ID NO:2 or the amino acid sequence set forth in SEQ ID NO:8, respectively. The same TdT variants reduce the overall synthesis error rate by 0.04%, 0.06% and 0.06% per step, respectively. Thus, said specific TdT variants according to the invention are more stable compared to TdT variants having the amino acid sequence set forth in SEQ ID NO:2 or set forth in SEQ ID NO:8.
[0126] In another embodiment, the present invention relates to a nucleic acid encoding a variant of a DNA polymerase of the poIX family, in particular TdT, capable of synthesizing a nucleic acid molecule without a template strand according to the present invention. The present invention also relates to an expression cassette of a nucleic acid according to the present invention. The present invention further relates to a vector comprising a nucleic acid or an expression cassette according to the present invention. The vector may be selected from a plasmid or a viral vector.
[0127] The nucleic acid encoding the DNA polymerase variant may be DNA (cDNA or gDNA), RNA, or a mixture of the two. The nucleic acid may be in single-stranded form, in duplex form, or a mixture of the two forms. The nucleic acid may contain modified nucleotides, including, for example, modified bonds, modified purine or pyrimidine bases, or modified sugars. The nucleic acid may be prepared by any method known to those skilled in the art, including chemical synthesis, recombination, mutagenesis, etc.
[0128] The expression cassette comprises all elements necessary for the expression of the TdT variant according to the invention, in particular the elements necessary for transcription and translation in the host cell. The host cell may be prokaryotic or eukaryotic. In particular, the expression cassette comprises a promoter and a terminator, and optionally an amplification factor. The promoter may be prokaryotic or eukaryotic. The following are examples of preferred prokaryotic promoters: Lacl, LacZ, pLacT, ptac, pARA, pBAD, the RNA polymerase promoters of bacteriophage T3 or T7, the polyhedrin promoter, the PR or PL promoters of lambda phage. The following are examples of preferred eukaryotic promoters: the CMV early promoter, the HSV thymidine kinase promoter, the SV40 early or late promoter, the mouse metallothionein-L promoter, and the LTR regions of certain retroviruses. In general, for the selection of a suitable promoter, those skilled in the art can advantageously refer to the work by Sambrook et al. (1989) or to the techniques described by Fuller et al. (1996; Immunology in Current Protocols in Molecular Biology).
[0129] The present invention relates to a vector carrying a nucleic acid or expression cassette encoding a TdT variant according to the invention. The vector is preferably an expression vector, i.e. the vector comprises the elements necessary for the expression of the variant in a host cell. The host cell may be a prokaryote, for example E. coli, or a eukaryote. The eukaryote may be a lower eukaryote, such as a yeast (for example P. pastoris or K. lactis) or a fungus (for example of the genus Aspergillus), or a higher eukaryote, such as an insect cell (for example Sf9 or Sf21), a mammalian cell or a plant cell. The cells may be mammalian cells, such as COS (green monkey cell line) (e.g., COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651), CHO (U.S. Pat. Nos. 4,889,803; 5,047,335; CHO-K1 (ATCC CCL-61), mouse cells and human cells. In certain embodiments, the cells are non-human and non-embryonic. The vector can be a plasmid, a phage, a phagemid, a cosmid, a virus, a YAC, a BAC, an Agrobacterium pTi plasmid, and the like. The vector may preferably include one or more elements selected from an origin of replication, a multiple cloning site, and a selection gene. In a preferred embodiment, the vector is a plasmid. The following are non-exhaustive examples of prokaryotic vectors: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pBR322 and pRIT5 (Pharmacia), pET (Novagen).The following are non-exhaustive examples of eukaryotic vectors: pWLNEO, pSV2CAT, pPICZ, pcDNA3.1(+)Hyg (Invitrogen), pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pCI-neo (Stratagene), pMSG, pSVL (Pharmacia); and pQE-30 (QLAexpress). Viral vectors are, in a non-exhaustive manner, adenovirus, AAV, HSV, lentivirus, etc. Preferably, the expression vector is a plasmid or a viral vector.
[0130] The sequence encoding the TdT variant according to the present invention may or may not contain a signal peptide. If the sequence does not contain a signal peptide, a methionine can be added to the N-terminus as necessary. In another alternative, a heterologous signal peptide may be introduced. This heterologous signal peptide may be derived from a prokaryote such as E. coli, or from a eukaryote, in particular a mammalian cell, an insect cell, or yeast.
[0131] The present invention relates to the use of a polynucleotide of an expression cassette or of a vector according to the present invention for transforming or transfecting a cell. The present invention relates to a host cell comprising a nucleic acid, expression cassette or vector encoding a TdT variant, and to its use for producing a TdT variant according to the present invention. The term "host cell" encompasses daughter cells resulting from the culture or propagation of this cell. In certain embodiments, the cell is non-human and non-embryonic.
[0132] The present invention also relates to a method for producing a TdT variant of the present invention, comprising transforming or transfecting a cell with a polynucleotide, expression cassette or vector according to the present invention; culturing the transfected / transformed cell; and recovering the TdT variant produced by the cell. In an alternative embodiment, the method for producing a TdT variant of the present invention comprises providing a cell comprising a polynucleotide, expression cassette or vector according to the present invention; culturing the transfected / transformed cell; and recovering the TdT variant produced by the cell. In particular, the cell may be transformed / transfected in a transient or stable manner with a nucleic acid encoding the variant. This nucleic acid may be included in the cell in the form of an episome or in the form of a chromosome. Methods for producing recombinant proteins are well known to those skilled in the art.
[0133] The TdT variants can be operatively linked to a linker moiety, including a covalent or non-covalent bond; an amino acid tag (e.g., poly-amino acid tag, poly-His tag, 6His tag, etc.); a chemical compound (e.g., polyethylene glycol); a protein-protein binding pair (e.g., biotin-avidin); affinity coupling; a capture probe; or any combination thereof. The linker moiety may be separate from the TdT variant or may be part of the TdT variant. An exemplary His tag for use with the modified TdT variants of the invention is MASSHHHHHHSSGSEKKIS- (SEQ ID NO: 6). The tag-linker moiety does not interfere with the nucleotide binding or catalytic activity of the TdT variant, allowing for easy purification and separation of the TdT variant.
[0134] The TdT variants according to the present invention are particularly advantageous for synthesis of nucleic acids without template strands. More specifically, the variants according to the present invention have a more flexible loop 1, which is more suitable for accommodating modified nucleotides that present greater steric hindrance than natural nucleotides. Also, the T264R mutation of SEQ ID NO: 2 or T245R of SEQ ID NO: 8 improves the interaction between TdT and DNA initiators.
[0135] The present invention therefore also relates to the use of a TdT variant according to the invention, in particular one described in application WO2016034807, for the synthesis of template-free nucleic acid molecules from 3'-OH modified nucleotides.
[0136] In another aspect, the present invention relates to a kit for the enzymatic synthesis of nucleic acid molecules, in particular without a template strand, said kit comprising: a. at least one TdT variant according to any one of the above embodiments; b. at least one 3'-O-modified nucleoside triphosphate, and c. At least one initiator, if necessary Includes.
[0137] In particular, the modified nucleoside triphosphate is a protecting group, which makes it possible to block / protect the 3'-OH, thus preventing it from reacting with other nucleosides. Thus, in particular, the kit comprises at least one 3'-O-protected nucleoside triphosphate.
[0138] In certain embodiments, the kit of the present invention comprises at least two TdT variants, preferably at least three TdT variants.When the kit comprises two or more TdT variants, the TdT variants in the kit can be different from each other.For example, the kit can be a mixture of the TdT variants of the present invention.
[0139] In some embodiments, the kit comprises a first TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:3, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:3, optionally less than 100% identical to SEQ ID NO:3, and a second TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:5, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:5, optionally less than 100% identical to SEQ ID NO:5.
[0140] In a more preferred embodiment, the kit of the invention comprises a first TdT variant comprising the amino acid sequence set forth in SEQ ID NO:3 and a second variant comprising the amino acid sequence set forth in SEQ ID NO:5.
[0141] In some embodiments, the kit of the invention comprises a first TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:9, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:9, optionally less than 100% identical to SEQ ID NO:9, and a second TdT variant comprising an amino acid sequence at least 70% identical to SEQ ID NO:11, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO:11, optionally less than 100% identical to SEQ ID NO:11.
[0142] In a more preferred embodiment, the kit of the invention comprises a first TdT variant comprising the amino acid sequence set forth in SEQ ID NO:9 and a second variant comprising the amino acid sequence set forth in SEQ ID NO:11.
[0143] The TdT variants and kits of the present invention are particularly suitable for the enzymatic synthesis of polynucleotides, i.e. nucleic acid molecules, without a template strand.
[0144] Therefore, the present invention also relates to a method for the enzymatic synthesis of a nucleic acid molecule without a template strand, according to which a primer strand is contacted with at least one nucleotide, preferably a 3'-OH modified nucleotide, in the presence of a TdT variant according to the present invention.
[0145] Accordingly, the present invention relates to a method for synthesizing a polynucleotide having a predetermined sequence, the method comprising: a. providing at least one initiator having a 3'-terminal nucleotide having a free 3'-hydroxyl; b. contacting said at least one initiator having a free 3'-O-hydroxyl with a 3'-O-blocked nucleoside triphosphate and a TdT variant according to any one of the above embodiments under extension conditions, such that said at least one initiator is extended by incorporation of a 3'-O-blocked nucleoside triphosphate to form a 3'-O-blocked extension fragment; and c. deblocking the extension fragment to form an extension fragment having a free 3'-hydroxyl; and d. Repeating steps b. and c. until a polynucleotide is formed by contacting the extended fragment obtained in step c. under extension conditions; Includes.
[0146] In a preferred embodiment, the TdT variants according to the invention can be used to carry out the synthesis methods described in application WO2015 / 159023, which is incorporated herein by reference.
[0147] Other features and advantages of the present invention will become more apparent from the following examples and results, which are, of course, non-limiting. EXAMPLES
[0148] Example 1 – Construction, expression and screening of TdT variants Construction of TdT variants The TdT variants of the present invention were created using the MEGAWHOP cloning method disclosed by Miyazaki K. MEGAWHOP cloning: a method of creating random mutagenesis libraries via megaprimer PCR of whole plasmids. Methods Enzymol. 2011; 498: pp. 399-406. Doi: 10.1016 / B978-0-12-385120-8.00017-6. PMID: 21601687.
[0149] Megaprimers were generated by PCR using a pair of primers, where at least one primer was mutagenic (containing a degenerate codon or a pre-designed mutation), following standard PCR amplification and molecular biology techniques. The purified megaprimers were combined with the TDT circular backbone plasmid (pet28 vector) in a second PCR step. After digestion with DpnI, the PCR products were electroporated into E. Cloni 10G cells (Lucigen). Transformants were selected on 2YT agar plates supplemented with 50 mg / L kanamycin. Plasmids encoding TdT variants were prepared either directly from the bacterial carpet of the transformation plate or from overnight liquid cultures (2YT supplemented with 0.5% glucose and 50 mg / L kanamycin).
[0150] Expression and Screening For screening, the plasmids encoding the TdT variants were retransformed into the commercially available E. coli strain BL21(DE3) (Novagen). Colonies that were able to grow in the kanamycin Petri dishes were isolated and labeled. Individual variants of TdT were produced, expressed, and purified in a 96-well format using Ni-NTA chromatography as described by Ybert et al., US Patent Application No. US2020 / 0002690. Protein quantity was determined by absorbance at 280 nm.
[0151] Example 2 - Study of the activity of TdT variants, particularly duplex and hairpin activity. The activity of the various TdT variants according to the invention was determined by the following tests and the results were compared with those obtained with the TdT of SEQ ID NO: 2 (reference) from which each of the variants is derived.
[0152] In this study, we monitor the TdT kinetics in the incorporation of 3'-terminal dNTPs as described in International Patent Application No. WO2020 / 099451. We developed short initiator DNA (iDNA) substrates that transition from single-stranded DNA to double-stranded DNA (dsDNA) upon incorporation of a single base (TGGCC for +A reactions and CAGCAAGGCT for +G reactions). Depending on the application, two types of iDNA were applied: hairpin-DNA, which mainly forms intramolecular dsDNA, or duplex-DNA, which forms symmetric dsDNA composed of two molecules (see FIG. 2). In the duplex assay, the energy effect of a single incorporated base is doubled, which is crucial for monitoring the +A or +T reactions that create an easily melted A=T pair.
[0153] Thus, in such a system, the formation of dsDNA reflects the enzymatic activity of TdT, and its formation can be monitored in real time by measuring the fluorescence of dsDNA-specific intercalating dyes (ethidium bromide, GelRed, SYBR Green). The specific activity of TdT variants was determined as the initial rate of GelRed fluorescence increase in the presence of 500 μM 3'ONH2 dNTP, 10 μM iDNA and 30 nM TdT.
[0154] result OP2 represents the purity of enzymatically generated DNA as determined by capillary electrophoresis. E12 represents the TGTTCCGGAAGAGCAACCTG DNA sequence synthesized at the end of AACTACCTGTACCGGC DNA attached to a solid support. Q21 represents the CGCACGCTAC DNA sequence synthesized at the end of GTATGGCGCGATGACTCG DNA attached to a solid support. Tm represents the melting temperature of the pure TdT variant, determined from thermal shift assay using SYPRO Orange dye. Deletion rate is the average value from our standard 24 primer set, which is about 50 bases long on average.
[0155] The results are detailed in Table 2 below. TIFF2024541312000003.tif136170
[0156] The activity and synthesis performance of TdT variants with SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5, respectively with mutations T264R+I298V, or C23A+T264R+I298V, or V262A+I298V, are depicted in Figure 3. The plot in panel A shows the enzymatic rate of the +A reaction in the TAGCT+A duplex test, and the plot in panel B indicates the enzymatic rate of the +G reaction with the CAGCAAGGCT+G hairpin.
[0157] Thus, the TdT variants having the amino acid sequences set forth in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 reduced the deletion rate for alanine from 0.55% to 0.36%, 0.32% and 0.40% per step, respectively, compared to the deletion rate of the TdT variant having the amino acid sequence set forth in SEQ ID NO:2. The same TdT variants reduced the overall synthesis error rate by 0.04%, 0.06% and 0.06% per step, respectively. Thus, said specific TdT variants according to the invention produce DNA strands of better quality.
[0158] Example 3 – Comparative Study This study examines the average substitutions, insertions and deletions of sequences synthesized with TdT variants of SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 compared to those obtained with TdT of SEQ ID NO:2.
[0159] 24 sequences are synthesized in duplicate for each TdT variant. Synthesis is carried out at 37°C in 0.5M cacodylate buffer pH 7.4 with 20μM enzyme, 2mM CoCl2, 500μM ONH2 nucleotide, 750pmol resin (10μM iDNA) in 20% DMSO, 50mM NaCl. Each synthesis includes TdT of SEQ ID NO:2 as a control. Percentage refers to the percentage of complete reads compared to the reference sequence).
[0160] The 24 sequences synthesized by each TdT variant were sequenced using an iSeq 100 System sequencer from Illumina, Inc. The percentages of deletions, insertions, and substitutions were calculated by comparing the sequences obtained from the sequencer with the target sequences.
[0161] The results are detailed in FIG.
[0162] In terms of the average value of deletions, compared to TdT of SEQ ID NO: 2, the TdT variants of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 are all better, especially the TdT variants of SEQ ID NO: 4 and SEQ ID NO: 5. The average value of insertions is also reduced compared to TdT of SEQ ID NO: 2. Thus, the TdT variants according to the invention produce DNA strands with fewer misintegrations, and as a result, the technical problem is fully solved by the TdT of the invention.
Claims
1. An amino acid sequence that is at least 70% identical to SEQ ID NO:2, the amino acid sequence comprises at least one amino acid substitution with a replacement amino acid at a position selected from a first group consisting of positions 23, 262, 264 and 298, or at a functionally equivalent position of each position in said first group; wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:2: an amino acid sequence at least 70% identical to SEQ ID NO:2; or An amino acid sequence that is at least 70% identical to SEQ ID NO:8, the amino acid sequence comprises at least one amino acid replacement with a replacement amino acid at a position selected from a second group consisting of positions 4, 243, 245 and 279, or at a functionally equivalent position of each position in said second group; wherein these positions are numbered by reference to the amino acid sequence set forth in SEQ ID NO:8: An amino acid sequence that is at least 70% identical to SEQ ID NO:8 A terminal deoxynucleotidyl transferase (TdT) variant comprising:
2. 2. The TdT variant of claim 1, wherein the substituted or replaced amino acid is selected from the group consisting of R, V, A, L, K, Q, T and G.
3. 3. The TdT variant of claim 1 or 2, wherein the at least one amino acid substitution is at position 298 or the at least one amino acid substitution is at position 279.
4. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least two substitutions at positions selected from the group consisting of positions 23, 262, 264 and 298; or An amino acid sequence at least 70% identical to SEQ ID NO:8, comprising at least two substitutions at positions selected from the group consisting of positions 4, 243, 245 and 279; A TdT variant according to any one of claims 1 to 3.
5. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least three substitutions at positions selected from the group consisting of positions 23, 262, 264 and 298; or An amino acid sequence at least 70% identical to SEQ ID NO:8, comprising at least three substitutions at positions selected from the group consisting of positions 4, 243, 245 and 279; A TdT variant according to any one of claims 1 to 4.
6. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least one amino acid substitution selected from I298V / T / L; or An amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid replacement selected from I279V / T / L; A TdT variant according to any one of claims 1 to 5.
7. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least one amino acid substitution selected from T264R / K / Q; or An amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid substitution selected from T245R / K / Q; A TdT variant according to any one of claims 1 to 6.
8. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least one amino acid substitution selected from V262A / T / G; or An amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid substitution selected from V243A / T / G; A TdT variant according to any one of claims 1 to 7.
9. an amino acid sequence at least 70% identical to SEQ ID NO:2, which contains at least one amino acid substitution selected from C23A / T; or An amino acid sequence at least 70% identical to SEQ ID NO:8 contains at least one amino acid substitution selected from C4A / T; A TdT variant according to any one of claims 1 to 8.
10. an amino acid sequence at least 70% identical to SEQ ID NO:2 is at least 70% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5; or An amino acid sequence at least 70% identical to SEQ ID NO:8 is at least 70% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11; A TdT variant according to any one of claims 1 to 9.
11. a. at least one TdT variant according to any one of claims 1 to 10; b. at least one 3'-O-modified nucleoside triphosphate, and c. Optionally, at least one initiator Including the kit.
12. The kit of claim 11 , wherein the kit comprises two TdT variants.
13. a first TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:3 and a second variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:5; or The first TdT variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:9, and the second variant comprises an amino acid sequence at least 70% identical to SEQ ID NO:
11. The kit of claim 12.
14. 1. A method for synthesizing a polynucleotide, the method comprising: a. providing at least one initiator having a 3'-terminal nucleotide with a free 3'-hydroxyl; b. contacting at least one initiator having a free 3'-O-hydroxyl with a 3'-O-blocked nucleoside triphosphate and a TdT variant according to any one of claims 1 to 10 under elongation conditions, such that the at least one initiator is elongated by incorporation of a 3'-O-blocked nucleoside triphosphate to form a 3'-O-blocked extension fragment; c. deblocking the extension fragment to form an extension fragment having a free 3'-hydroxyl; and d. Repeating steps b. and c. by contacting at least the extended fragment obtained in step c. under extension conditions until a polynucleotide is formed; A method for synthesizing a polynucleotide, comprising:
Citation Information
Patent Citations
Chimeric terminal deoxynucleotidyl transferases for template-free enzymatic synthesis of polynucleotides
WO2021116270A1
Template-free enzymatic polynucleotide synthesis using dismutationless terminal deoxynucleotidyl transferase variants
WO2021122539A1
Method and apparatus for enzymatic synthesis of polynucleotides
WO2021170524A1
